Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC
This prospective, unicentric, open-labe phase I study is to evaluate the safety and effect of autologous cytotoxic T lymphocyte immunotherapy combination with PD-1 inhibitor in the second-line treatment of stage IIIB/IIIC/IV non-small cell lung cancer.
Non-small Cell Lung Cancer|Second-line Treatment
BIOLOGICAL: CTL|BIOLOGICAL: Toripalimab
Objective response rate (ORR), ORR was calculated by the percentage of patients with a confirmed complete (CR) or partial response (PR)., 2 years
In the stage IIIB/IIIC/IV NSCLC, patients received Toripalimab Injection (PD-1 inhibitor) 240mg, d1; CTL cells venous re-transfusion \>=1x10\^9, d14; Q3W; till disease progresion, or intolerable adverse reactions.